About Steminent
Management Team
Scientific and Clinical Advisors
Technology
Stemchymal® Therapeutic Advantages
Stemchymal® Application Fields
Clinical Programs
Stemchymal® for PolyQ SCA
Stemchymal® for Huntington’s Disease (HD)
Investor Relations
Financials
Financial Results
Earnings Conference
Shareholder Services
Material Information
IR News
Corporate Governance
News
Media Coverage
Hiring
Contact Us
Privacy and Security Policy.
第一金、日商DCI等參投!仲恩生醫4.5億台幣現增到位9月申請公開發行 –環球生技月刊
Taipei, Taiwan, August 31, 2023
今(31)日,罕病細胞新藥開發公司仲恩生醫宣布,已完成公開發行前的最後一輪4.5億元現金增資目標,現增金額全數到位,截至此輪募資,仲恩受到眾多知名…
全文請見環球生技月刊
。